Clinical Trials Logo

Anticoagulant clinical trials

View clinical trials related to Anticoagulant.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06020560 Recruiting - Clinical trials for Venous Thromboembolism

Study of Low Molecular Weight Heparins

DANHEP
Start date: March 23, 2023
Phase: Phase 4
Study type: Interventional

DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. The most frequently used parenteral anticoagulants in Denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. The two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. Importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. The aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.

NCT ID: NCT04867200 Recruiting - Anticoagulant Clinical Trials

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers

Start date: April 27, 2021
Phase: Phase 1
Study type: Interventional

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-344

NCT ID: NCT04673695 Recruiting - Anticoagulant Clinical Trials

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

Start date: November 13, 2020
Phase: Phase 1
Study type: Interventional

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-344

NCT ID: NCT04257487 Recruiting - Clinical trials for Venous Thromboembolism

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Jason
Start date: December 21, 2020
Phase: Phase 3
Study type: Interventional

The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.

NCT ID: NCT04010955 Recruiting - Atrial Fibrillation Clinical Trials

Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)

(ADD-ON)
Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

This study aims to compare the effectiveness and safety regarding treatment with standard anticoagulant only or adding antiplatelet to anticoagulant in patients with non-valvular atrial fibrillation and significant atherosclerosis including extracranial, intracranial, coronary or peripheral artery.

NCT ID: NCT03772457 Recruiting - Clinical trials for Intracranial Hemorrhages

Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

Start date: January 18, 2019
Phase:
Study type: Observational

This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode MRI infarct volume / MMP-9 on hemorrhagic transformation after anticoagulation therapy.